Experimental combo targets relapsed blood cancers after transplant
NCT ID NCT03912064
First seen Sep 30, 2025 · Last updated Apr 28, 2026 · Updated 21 times
Summary
This early-phase study tests a new treatment for people whose blood cancer (like AML or MDS) has returned after a donor stem cell transplant. The treatment combines a special type of donor immune cell infusion with an immunotherapy drug (ipilimumab) to help fight the cancer. The main goal is to find the safest dose and understand side effects in about 25 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.